Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over

BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamai, Hideyuki, Shingaki, Naoki, Ida, Yoshiyuki, Shimizu, Ryo, Maeshima, Shuya, Okamura, Junpei, Kawashima, Akira, Nakao, Taisei, Hara, Takeshi, Matsutani, Hiroyoshi, Nishikawa, Izumi, Higashi, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Prospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522558/
https://www.ncbi.nlm.nih.gov/pubmed/33033572
http://dx.doi.org/10.4254/wjh.v12.i9.672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522558/
https://www.ncbi.nlm.nih.gov/pubmed/33033572
http://dx.doi.org/10.4254/wjh.v12.i9.672

Ejemplares similares